India’s accession to the Patent Cooperation Treaty on December 7, 1998, fundamentally transformed the landscape for both inbound and outbound patent filings. For Indian applicants seeking protection across multiple jurisdictions, the PCT provides a single-window mechanism of unmatched procedural efficiency. For foreign applicants targeting the Indian marketone of the world’s most consequential pharmaceutical, technology and manufacturing economies the PCT national phase offers a carefully regulated pathway into the Indian patent system administered by the Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM). Understanding the full architecture of PCT procedure as it interfaces with Indian domestic law under the Patents Act, 1970, as amended and the Patents Rules, 2003, as amended in 2016 and 2021, is essential for any practitioner or applicant who takes the Indian market seriously.
This article provides a comprehensive analysis of PCT filing procedure, the international phase, Chapter I and Chapter II proceedings, national phase entry requirements under Indian law, examination practice before the Indian Patent Office and the strategic considerations that distinguish successful from unsuccessful prosecution in this jurisdiction. Where Indian case law and administrative decisions bear on PCT-specific issuesincluding amendments, the treatment of the international search report and written opinion and the distinctive requirements of Sections 3 and 4 of the Patents Act, 1970these are examined in depth. The article also addresses the particular challenges faced by pharmaceutical and software applicants pursuing Indian national phase entry and the intersection of PCT procedure with India’s sui generis approach to patentability.
The PCT Framework and India’s Participation
The Patent Cooperation Treaty, administered by the World Intellectual Property Organization (WIPO) under the Washington Treaty of 1970, provides a unified mechanism for filing patent applications in multiple contracting states through a single international application. India’s accession brought with it designation as both a receiving office and, subsequently, a designated and elected office. The Indian Patent Office (IPO), specifically the branch at the Mumbai office, was designated as a receiving office for Indian applicants and resident nationals, enabling the filing of PCT international applications directly before the IPO in addition to the International Bureau in Geneva.
The governing domestic framework for PCT national phase entry is Rule 20 of the Patents Rules, 2003, read alongside Chapter XVI of the same Rules (Rules 76 to 82), which implement the requirements of the Patents Act, 1970, in respect of international applications. The Act itself addresses international applications through Sections 138 to 142, inserted by the Patents (Amendment) Act, 2002, with effect from January 1, 2005. These provisions establish the legal basis for treating a PCT international application as a deemed application under the Act upon national phase entry, subject to the conditions and formalities prescribed therein.
The International Phase: Structure and Procedure
A PCT international application progresses through a structured international phase before national phase entry. Understanding this phase is critical because decisions madeand documents generatedduring the international phase have direct bearing on the prosecution strategy adopted upon national phase entry into India.
Upon filing, every international application is assigned to an International Searching Authority (ISA). Under the agreement between the IPO and WIPO, the Indian Patent Office functions as an ISA for applications filed by Indian applicants. For most foreign applicants entering India, the ISA will typically be the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), the Korean Intellectual Property Office (KIPO) or another authority designated by the receiving office. The ISA conducts a prior art search and issues a Written Opinion (WO/ISA) alongside the International Search Report (ISR). These documents, while not binding on the Indian Patent Office as a designated office, are highly consequential in practicethey represent the first rigorous assessment of patentability across the claims as filed and the examiner conducting the First Examination Report (FER) in India will inevitably be influenced by the reasoning in the WO/ISA, particularly when the same prior art documents are cited.
Chapter II of the PCT, set out in Articles 31 to 42, provides an optional mechanism for applicants to obtain a more thorough prior art examination before the International Preliminary Examining Authority (IPEA). A demand for Chapter II examination must be filed before the expiry of whichever is later: three months from the date of transmittal of the ISR and WO/ISA or twenty-two months from the priority date. The IPEA issues an International Preliminary Report on Patentability (IPRPChapter II), which again is not binding on the Indian Patent Office but which shapes the prosecution history and may be relied upon strategically by the applicant to demonstrate that the claims have survived international scrutiny.
Where the applicant elects not to file a Chapter II demand, the International Bureau transmits the Written Opinion of the ISA as the IPRP Chapter I at the expiry of thirty months. Either document becomes part of the published application file and is accessible to the IPO examiner.
National Phase Entry in India: The Thirty-Month Deadline and Formal Requirements
Under Article 22 of the PCT, as applied in India, national phase entry must be effected within thirty months of the priority date. This thirty-month period represents the outer limit of the international phase and its expiry without national phase entry results in the deemed withdrawal of the international application insofar as India is concerned. Rule 76 of the Patents Rules, 2003, operationalises this requirement.
The formal requirements for national phase entry before the Indian Patent Office are both substantive and procedural. The applicant must file Form 1 (application for grant of patent), which serves as the national phase entry request and identifies the international application number and filing date. Form 2 (provisional or complete specification)in practice always a complete specification for PCT national phase entry, being the specification as filed internationally, optionally with amendmentsmust be filed along with the required translation into English where the international application was filed in another language. India accepts English-language international applications without translation, which is a practical convenience for the majority of PCT applicants targeting the Indian market.
Form 3, the statement and undertaking regarding foreign applications under Section 8 of the Patents Act, 1970, is mandatory and represents one of the most frequently mishandled formalities in Indian PCT prosecution. Section 8 requires that an applicant who has applied or is applying for patents in respect of the same or substantially the same invention in other countries must disclose, within the prescribed time, the filing date, application number and subsequently, upon request by the Controller, the details of the examination conducted by foreign patent offices, including any objections, prior art cited and the claims allowed or rejected. The obligation under Section 8 is continuing throughout prosecution and failure to comply has historically been treated as a ground for revocation. In Chemtura Corporation v. Union of India, 2009 (40) PTC 491 (Del), the Delhi High Court emphasised that the Section 8 obligation is not a mere procedural technicality but a substantive disclosure requirement going to the integrity of the patent system. The court held that the obligation extends to filing updated information as foreign prosecution progresses and that wilful non-disclosure could attract revocation. For PCT applicants, Form 3 must be filed at the time of national phase entry disclosing all corresponding foreign applications, with updates filed within three months of receiving a communication from a foreign patent office in respect of any corresponding application.
Form 5, the declaration as to inventorship, must also accompany national phase entry. Where inventors have been declared in the international application, this information can be carried forward, but the Form 5 must be formally executed in conformity with Indian requirements.
The national phase entry fee must be paid in accordance with the First Schedule to the Patents Rules, 2003, with concessions available for natural persons, start-ups, small entities and educational institutions as defined under the Rules, following the amendments introduced in 2021. The grant of such concessions to PCT national phase applicants has materially reduced the cost of entering India for individual inventors and small enterprises.
Publication and the Request for Examination
Under Section 11A of the Patents Act, 1970, every applicationincluding a PCT national phase applicationis published ordinarily eighteen months from the priority date. Since national phase entry occurs at thirty months, publication will typically have already taken place at the time of entry, given that publication is calculated from the priority date and not from the national phase entry date. The consequence is that applications entering national phase in India are often published before the formal national phase entry procedures are completed. This creates a minor but practically significant asymmetry: third parties may file pre-grant oppositions under Section 25(1) of the Act from the date of publication, meaning the opposition window commences before the applicant has even completed national phase formalities.
A request for examination must be filed under Form 18 (or Form 18A for expedited examination) within forty-eight months of the priority date, pursuant to Rule 24B of the Patents Rules, 2003. The forty-eight-month deadline is absolutefailure to file a request for examination within this period results in the application being treated as withdrawn. For applicants who enter national phase at or near the thirty-month deadline, there is an eighteen-month window to file the request for examination. This window is frequently used strategically to assess the commercial potential of the invention before committing to the cost of examination. The request for expedited examination under Rule 24C, introduced by the 2016 amendments, is available to applicants who have filed a corresponding application in a country with which India has an agreement on Patent Prosecution Highway (PPH) or to applicants falling within certain priority categories including start-ups, small entities and applicants where national security or public health considerations apply.
First Examination Report and the Role of the International Search Report
Upon the filing of a request for examination, the application is allotted to an examiner who issues the First Examination Report (FER) under Section 12 of the Patents Act, 1970. The FER is a comprehensive document addressing compliance with formal requirements, patentability under Sections 2(1)(j), 3, 4 and 10 of the Act, unity of invention and prior art. The examiner is not bound by the findings of the ISA or IPEA and the IPO is not a designated office that gives automatic effect to positive findings from the international search.
In practice, however, the ISR and Written Opinion heavily influence FER drafting. Where the ISA has cited prior art, those same documents invariably appear in the FER. Where the Written Opinion raised objections under Article 33 of the PCT corresponding to Section 3(d) or Section 3(k) of the Indian Act, the FER will typically raise analogous domestic objections. The practitioner’s strategy in responding to the FER must therefore grapple with the same prior art and the same conceptual objections as were raised internationally, but now interpreted through the specificand often more stringentlens of Indian patentability law.
The response to the FER must be filed within twelve months of its issuance and the hearing, if not resolved, must be concluded within the period prescribed under the Act. Amendments to the claims may be made during this stage but are subject to the constraint under Section 59 of the Act: no amendment shall be permitted to introduce new matter or to enlarge the scope of the claims. This constraint, which mirrors but is independent of Rule 137 of the PCT, means that amendments made during the international phase or as part of Article 34 proceedings cannot automatically be imported into the Indian national phase if they would contravene Section 59.
Patentability Challenges in the Indian National Phase: Section 3 and the PCT Applicant
The single most consequential difference between national phase prosecution in India and prosecution before the EPO or USPTO is the scope and application of Section 3 of the Patents Act, 1970, which enumerates categories of subject matter that are not inventions for the purposes of the Act. These exclusions are not identical to any international standard and represent a deliberate policy choice by the Indian legislature.
Section 3(d) has attracted the most international commentary and litigation. It provides that the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance and the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant, are not inventions. The Explanation to Section 3(d) provides that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substances shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy.
In Novartis AG v. Union of India, (2013) 6 SCC 1, the Supreme Court of India delivered the most significant patentability judgment in Indian IP history in the context of a PCT-derived national phase application. The application in question concerned the beta crystalline form of imatinib mesylate (Gleevec/Glivec). The Court, upholding the rejection of the application by the Intellectual Property Appellate Board and the Patent Office, held that the beta crystalline form did not satisfy the Section 3(d) threshold as the applicant had not demonstrated a significant enhancement in therapeutic efficacy over the known free base form of imatinib. The Court drew a sharp distinction between physico-chemical properties such as improved flowability, hygroscopicity and stabilitywhich it held were insufficient to establish efficacy enhancementand therapeutic efficacy properly so called. The judgment is binding authority for every PCT applicant in the pharmaceutical space: polymorphs, salts and new forms of known active pharmaceutical ingredients must demonstrate enhanced therapeutic efficacy to survive the Section 3(d) hurdle.
Section 3(k) poses comparable challenges for software and computer-implemented inventions. The provision excludes a mathematical or business method or a computer programme per se or algorithms from patentability. The Controller General has issued Guidelines for Examination of Computer Related Inventions (CRI Guidelines), most recently revised in 2017, which attempt to harmonise India’s approach with the functional claiming methodology prevalent at the EPO and USPTO. The CRI Guidelines permit claims directed to a computer-implemented method that produces a technical effect beyond the normal physical interactions between software and hardware, but the application of this standard remains inconsistent across examiners. In Ferid Allani v. Union of India & Others, W.P. (C) 7416/2014, the Delhi High Court remanded a PCT national phase application back to the Patent Office with directions to reconsider the rejection of computer-implemented claims under Section 3(k), holding that the Office had applied too broad an exclusion without adequately examining whether a technical contribution existed. The judgment has been relied upon by practitioners to resist blanket Section 3(k) rejections in FER responses, with varying success depending on the particular examiner.
Pre-Grant Opposition in the PCT National Phase
The pre-grant opposition regime under Section 25(1) of the Patents Act, 1970, is particularly active in the context of PCT national phase applications in the pharmaceutical sector. Any person may file a pre-grant opposition after publication of the application and the grounds availablewhich include prior claiming, prior publication, prior use, obviousness, non-patentability under Sections 3 and 4 and insufficiency of disclosureare substantially broader than pre-grant opposition grounds in most other jurisdictions.
In F. Hoffmann-La Roche Ltd. v. Cipla Ltd., 2008 (37) PTC 71 (Del DB), the Division Bench of the Delhi High Court addressed a PCT-derived national phase application for erlotinib hydrochloride in the context of an infringement action and interim injunction proceedings. The Court’s analysis of the Section 3(d) issue and its refusal to grant an injunction in part because the patent’s validity was seriously disputed on Section 3(d) grounds, demonstrated that the PCT prosecution history including the international search and the file wrapper was actively scrutinised by the court in assessing prima facie validity. This principle places a premium on building a strong file history during the international phase that anticipates Indian patentability standards.
Post-Grant Considerations and Working Requirements
Once granted through the PCT national phase, a patent in India is subject to the same obligations as a directly-filed patent. Among these, the annual statement of working under Form 27 is the most distinctive to the Indian system. Section 83 and Section 146 of the Patents Act, 1970, read with Rule 131, require every patentee and every licensee to furnish, within three months of the end of each year, a statement indicating the extent to which the invention has been commercially worked in India. Failure to file Form 27 is an offence under Section 122 and may inform a compulsory licensing proceeding under Section 84. PCT national phase patentees who are predominantly foreign entities frequently overlook this obligation and the CGPDTM has, in recent years, initiated enforcement action against defaulters.
In Bayer Corporation v. Union of India, 2014 (60) PTC 277 (Bom), the Bombay High Court upheld India’s first compulsory licence granted by the Controller General, which concerned the cancer drug sorafenib (Nexavar). The patent in question had entered the Indian register through national phase entry. The Controller’s finding that the reasonable requirements of the public had not been satisfied, that the drug was not available at a reasonably affordable price and that it was not being manufactured to an adequate extent in India, directly implicates the Form 27 working statement regime. The decision remains the most consequential intersection of PCT national phase grant with India’s compulsory licensing framework.
Reinstatement and Restoration in the PCT Context
A PCT national phase application that fails to meet the thirty-month deadline due to inadvertent error, missed correspondence or miscalculation of the priority date may in limited circumstances be reinstated under Rule 49.6 of the PCT Regulations, provided the receiving office or designated office permits restoration of the right of priority or delayed national phase entry on the basis of unintentional delay. Under Rule 80B of the Patents Rules, 2003, the Controller has the discretion to condone delays in the filing of national phase documentation where sufficient cause is shown. However, the IPO has not historically been liberal in granting such relief and the practitioner must approach restoration applications with carefully documented evidence of the inadvertent nature of the delay.
Strategic Observations for Indian National Phase Prosecution
The practitioner advising a PCT applicant entering India must calibrate strategy around several India-specific variables that do not arise in the same form before the EPO or USPTO. The Section 8 obligation demands proactive case management the applicant must track corresponding prosecution across all jurisdictions and ensure that allowances, rejections and examination communications are reported to the Indian Patent Office on a rolling basis. The drafting of claims for Indian prosecution must anticipate the Section 3(d) and Section 3(k) exclusions from the outset, particularly for pharmaceutical and software applicants claims that survive examination in Munich or Washington may face objections in New Delhi or Mumbai that require substantive amendment rather than mere argument.
The use of the international phase to build a positive prosecution historyby filing an Article 34 response to the Written Opinion that addresses Indian-specific concernsis under utilized by most applicants but represents a genuine opportunity to shape the national phase file wrapper before entry. A detailed response to a Written Opinion that explicitly addresses Section 3(d) or Section 3(k) concerns, supported by comparative efficacy data or technical effect declarations, can substantially reduce the scope of the FER objections and compress prosecution timelines.
Conclusion
The Patent Cooperation Treaty as implemented in Indian domestic law represents a sophisticated interface between an internationally standardized procedure and a jurisdiction with highly distinctive patentability standards. The thirty-month national phase entry deadline, the extensive formal requirements under the Patents Rules, 2003, the continuing obligation under Section 8 and the application of Section 3’s exclusionary categories to nationally entered PCT applications collectively create a prosecution environment that rewards advance planning and penalizes the assumption that favourable international outcomes will translate automatically into Indian grant.
The trajectory of Indian PCT practice points toward greater procedural efficiency the IPO’s adoption of e-filing, the Patent Prosecution Highway arrangements being negotiated and the expedited examination framework under Rule 24C all signal an administrative intent to reduce pendency and align Indian practice more closely with international timelines. But India’s substantive patentability law, anchored by the Supreme Court’s judgment in Novartis and Parliament’s deliberate retention of Section 3(d) and Section 3(k) in their present form, will continue to set India apart from any convergence toward a uniform global patentability standard. For practitioners, this is not a limitation to be circumvented but a terrain to be understood one in which thorough preparation during the international phase, meticulous attention to national phase formalities and deep engagement with India’s patentability jurisprudence remain the foundations of successful prosecution.
References
- Patents Act, 1970 (as amended) https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_31_1_patent-act-1970-11march2015.pdf
- Patents Rules, 2003 (as amended) https://ipindia.gov.in/writereaddata/Portal/ev/sections/ps108.html
- WIPO PCT Applicant’s GuideIndia National Phase https://www.wipo.int/pct/en/appguide/index.jsp
- Patent Cooperation Treaty https://www.wipo.int/pct/en/texts/articles/atoc.html
- Guidelines for Examination of Computer Related Inventions, 2017 https://ipindia.gov.in/writereaddata/Portal/Images/pdf/Revised_Guidelines_for_Examination_of_Computer_Related_Inventions__CRIs_-dated_30_June_2017.pdf
- Novartis AG v. Union of India, (2013) 6 SCC 1 https://main.sci.gov.in/judgment/judis/40212.pdf
- Bayer Corporation v. Union of IndiaController General Order on Compulsory Licence https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_69_1_CL-Order.pdf
- DPIITNational IPR Policy, 2016 https://dpiit.gov.in/sites/default/files/National_IPR_Policy_English.pdf
- CGPDTMPatent Office Practice and Procedure Manual https://ipindia.gov.in/patent-manual.htm
- WTO TRIPS Agreement, Article 27 https://www.wto.org/english/docs_e/legal_e/27-trips_04d_e.htm
Articles Case Laws Copyright Article Copyright case laws Patent Article patent case laws Trademark Article Trademark case laws